177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Journal of Clinical Oncology · 20.12.2025 · 43 (36) · 3812-3821
DOI: 10.1200/jco-25-01553 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.12.2025. Verfasst von Amar U Kishan und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Radiosurgery, Prostatic Neoplasms, Lutetium, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)–targeting radioligand therapy to SBRT would improve outcomes. METHODS The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a v M1b) and lesion count (1 v 2-3 v 4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of 177 Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically at prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959 ). RESULTS From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and 177 Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and 177 Lu + SBRT n = 45). At a median follow-up of 22 months, the addition of 177 Lu to SBRT significantly improved PFS (17.6 months [95% CI 15 months to not reached] v 7.4 months [95% CI, 6.0 to 13.5 months]; hazard ratio, 0.37 [95% CI, 0.22 to 0.61], P < .0001). The only grade 3 adverse events were lymphopenia (two patients [4.8%] in the SBRT group and three patients [6.7%] in the 177 Lu + SBRT group). Prognostic biomarkers for PFS were identified. CONCLUSION Compared with SBRT alone, the addition of 177 Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
- Department of Urology, University of California, Los Angeles, Los Angeles, CA.
- Greater Los Angeles VA Medical Center, Los Angeles, CA.
- Department of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA.
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
- Department of Radiation Oncology, University of Washington, Seattle, WA.
ORCID-Profile: Amar U Kishan, Luca F Valle, Holly Wilhalme, Jesus E Juarez-Casillas, T Martin Ma, Zachary Ells, Michael Lauria, Catherine Meyer, Joanne B Weidhaas, Kristen McGreevy, Sophia Parmisano, Wayne Brisbane, Robert E Reiter, Paul C Boutros, Michael L Steinberg, Jeremie Calais
Förderung
- NCI NIH HHS
Zitieren
APA
Kishan, A. U., Valle, L. F., Wilhalme, H., Felix, C., Nabong, R., Juarez-Casillas, J. E., Flores, K., Ma, T. M., Ludwig, V., Nakayama, M., Ells, Z., Dahlbom, M., Lauria, M., Meyer, C., Cao, M., Weidhaas, J. B., Telesca, D., McGreevy, K., Nickols, N. G., …, & Calais, J. (2025). 177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. Journal of Clinical Oncology, 43(36), 3812-3821. https://doi.org/10.1200/jco-25-01553
Vancouver
Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, et al. 177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. Journal of Clinical Oncology. 2025;43(36):3812-3821. doi:10.1200/jco-25-01553
BibTeX
@article{Kishan2025,
author = {Kishan, Amar U and Valle, Luca F and Wilhalme, Holly and Felix, Carol and Nabong, Rejah and Juarez-Casillas, Jesus E and Flores, Kevin and Ma, T Martin and Ludwig, Vinicius and Nakayama, Mariko and Ells, Zachary and Dahlbom, Magnus and Lauria, Michael and Meyer, Catherine and Cao, Minsong and Weidhaas, Joanne B and Telesca, Donatello and McGreevy, Kristen and Nickols, Nicholas G and Karasik, Danielle and Parmisano, Sophia and Basehart, T Vincent and Brisbane, Wayne and Marks, Leonard and Rettig, Matthew B and Reiter, Robert E and Boutros, Paul C and Allen-Auerbach, Martin and Czernin, Johannes and Steinberg, Michael L and Calais, Jeremie},
title = {177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {36},
pages = {3812--3821},
doi = {10.1200/jco-25-01553}
}
EUVIMED